SCHEMBL1573418

SCHEMBL1573418

Cc1c(C(=O)c2ccc(N)c(C(=O)O)c2)c2ccccn2c1-c1cccc(OCC(=O)NCCCCCCNC(=O)COc2cccc(-c3c(C)c(C(=O)c4ccc(N)c(C(=O)O)c4)c4ccccn34)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
HTT P42858 1/20 0.41
MAPT P10636 4/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
APAF1 O14727 1/20 0.39
G6PD P11413 1/20 0.39
PABPC1 P11940 1/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
SAE1 Q9UBE0 1/20 0.39
UBA2 Q9UBT2 1/20 0.39
MAPK1 P28482 1/20 0.39
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PKM P14618 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4496163 0.96 KMT2A (0.42) KMT2AMEN1HTTMAPTALDH1A1
SCHEMBL1572827 0.92 MEN1 (0.42) KMT2AMEN1HTTMAPTALDH1A1
SCHEMBL4513945 0.89 KMT2A (0.41) KMT2AMEN1HTTMAPTALDH1A1
SCHEMBL1573417 0.87 KMT2A (0.39) KMT2AMEN1HTTMAPTALDH1A1
SCHEMBL1572786 0.85 ALDH1A1 (0.41) KMT2AMEN1HTTMAPTALDH1A1
SCHEMBL4509038 0.85 ALDH1A1 (0.40) KMT2AMEN1HTTMAPTALDH1A1
SCHEMBL4500632 0.85 ALDH1A1 (0.40) KMT2AMEN1HTTMAPTALDH1A1
SCHEMBL1573141 0.83 ALDH1A1 (0.41) KMT2AMEN1HTTMAPTALDH1A1
SCHEMBL4496158 0.83 KMT2A (0.40) KMT2AMEN1HTTMAPTALDH1A1
SCHEMBL4509501 0.81 KMT2A (0.41) KMT2AMEN1HTTMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 US claimed
EP-2018165-B1 FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI AVENTIS (FR) 2011-04-13 EP claimed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 US claimed
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 US disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS FGF2, FGFR1, FGF1 KMT2A 3395/4885MEN1 621/4885HTT 4673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.